Target Price | $67.07 |
Price | $29.77 |
Potential |
125.30%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Avidity Biosciences Inc 2026 .
The average Avidity Biosciences Inc target price is $67.07.
This is
125.30%
register free of charge
$96.00
222.47%
register free of charge
$48.00
61.24%
register free of charge
|
|
A rating was issued by 14 analysts: 14 Analysts recommend Avidity Biosciences Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of
125.30%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 10.90 | 7.65 |
14.02% | 29.85% | |
EBITDA Margin | -3,451.01% | -6,689.74% |
41.29% | 93.85% | |
Net Margin | -3,178.73% | -6,115.23% |
12.90% | 92.38% |
12 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.89 | -3.90 |
0.69% | 34.95% | |
P/E | negative | |
EV/Sales | 272.56 |
5 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Avidity Biosciences Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
Needham |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
Needham:
Locked
➜
Locked
|
Mar 17 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.